T2 Biosystems (T2 Biosystems) Buyback Yield % : -211.16 (As of Apr. 27, 2024)

View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

T2 Biosystems's current buyback yield was -211.16%.

T2 Biosystems Buyback Yield % Historical Data

The historical data trend for T2 Biosystems's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems Buyback Yield % Chart

T2 Biosystems Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buyback Yield %

Get a 7-Day Free Trial

-11.22

-46.46

-23.25

-266.16

-207.06

T2 Biosystems Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Buyback Yield %	Get a 7-Day Free Trial															-38.41	-505.82	-430.70	-100.29	-12.49

Competitive Comparison of T2 Biosystems's Buyback Yield %

For the Diagnostics & Research subindustry, T2 Biosystems's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

T2 Biosystems's Buyback Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's Buyback Yield % falls into.

T2 Biosystems Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

T2 Biosystems's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	52.731)	/	25.4663345
	=	-207.06%

T2 Biosystems's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0.795)	*	4	/	25.4663345
	=	-12.49%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Dec. 2023) data.

T2 Biosystems Buyback Yield % Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

T2 Biosystems (T2 Biosystems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Hartwell Avenue, Lexington, MA, USA, 02421

Website

https://www.t2biosystems.com

T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.

Executives

Cr Group L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p.	10 percent owner	C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs	officer: General Counsel	12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague	officer: Chief Financial Officer	101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii	director, officer: See Remarks	61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin	officer: Chief Commercial Officer	101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay	officer: SVP, Operations	101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja	officer: Chief Medical Officer	101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams	director	101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare	officer: Chief Commercial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Thierry Bernard	director	101 HARTWELL AVENUE, LEXINGTON MA 02421